Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

“Future studies should investigate the role of tumor profiling in guiding post-CDK4/6 inhibitor treatment selection and assess emerging targeted therapies in this setting, such as antibody-drug ...

The Institute of Cancer Research, London, is seeking partners to continue the development of a breast cancer gene signature for predicting resistance/ sensitivity to aromatase inhibitors and/or CDK4/6 ...

While the use of CDK4/6 inhibitors combined with endocrine therapy have significantly improved outcomes in patients with HR-positive, HER2-negative metastatic breast cancer, Pedram Razavi ...

While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion. VERZENIO (abemaciclib ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion. LAS VEGAS ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...